AHCC05
Read about the AHCC 05 trial, a completed Phase I/II study on SIR-Spheres plus Sorafenib as first-line treatment for non-resectable hepatocellular carcinoma.
Trial summary of AHCC 05
AHCC 05 | Phase I/II Study of SIR-Spheres plus Sorafenib (Chemo-Radiotherapy) as First Line Treatment in Patients with Non-Resectable Primary Hepatocellular Carcinoma |
|---|---|
Status | Completed in June 2009 with recruitment of 35 patients. Published in PLoS ONE 2014 9(3):e90909. doi: 10.1371/journal.pone.0090909. |
Contributing Principal | Pierce Chow (SGH, Singapore), Anthony Goh (SGH, Singapore), Soo Khee Chee (NCC, Singapore), Tan Say Beng (SCRI, Singapore), Alexander Chung (SGH, Singapore), Lai Hee Kit (SGH, Singapore), Tay Kiang Hiong (SGH, Singapore), Richard Lo Hoau Gong (SGH, Singapore), Donald Poon Yee Hee (NCC, Singapore), Choo Su Pin (NCC, Singapore), Han Ho Seong (Seoul, Korea), Harjit Singh (Selayang, Malaysia), Khin Maung Win (Yangon, Myanmar) |
Protocol Chair | Pierce Chow |